Golimumab is a recombinant human monoclonal antibody of the IgG1 subclass. It binds to tumor necrosis factor alpha (TNF-α) and prevents the induction of interleukins (IL-6 and -8), granulocyte-colony stimulating factor, and granulocyte-macrophage colony stimulating factor, which are proinflammatory cytokines that bring about inflammatory diseases.